文献速递心脑血管急症重症综合管理与镇静镇痛

强化降压与脑出血DWI高信号病灶:ATACH-2随机试验的探索性分析

Intensive Blood Pressure Lowering and DWI Lesions in Intracerebral Hemorrhage: Exploratory Analysis of the ATACH-2 Randomized Trial.
PubMed 文献 · Neurocrit Care · 2021-07-22
一句话结论急性脑出血强化降压至收缩压110–139 mmHg不增加DWI高信号病灶频率,病灶与90天死亡或残疾无显著关联。

该研究为ATACH-2随机试验的探索性亚组分析,纳入171例具备MRI序列的急性脑出血患者,比较静脉尼卡地平强化降压(收缩压目标110–139 mmHg)与标准降压(140–179 mmHg)。DWI高信号病灶总体发生率25%,强化组25%对标准组24%(RR 1.01,95%CI 0.71–1.43,P=0.97),无显著差异。血肿体积>30 cm³为病灶存在的独立预测因素(校正RR 2.41,95%CI 1.00–5.80)。病灶有无与90天死亡或残疾频率相似。提示强化降压不增加DWI病灶,病灶形成可能另有机制。

要点

  • 急性脑出血患者强化降压至收缩压110–139 mmHg(静脉尼卡地平)不增加DWI高信号病灶:25% vs 24%,RR 1.01(95%CI 0.71–1.43,P=0.97)。
  • DWI高信号病灶在急性脑出血患者中总体发生率25%(亚组171例中)。
  • 血肿体积>30 cm³是DWI高信号病灶存在的独立预测因素:校正RR 2.41(95%CI 1.00–5.80)。
  • DWI高信号病灶患者与无病灶者90天死亡或残疾频率相似。
  • 该分析为探索性亚组,仅171例具备MRI序列,结论需前瞻性验证。

适用人群与场景

  • 急性脑出血患者,来自ATACH-2随机试验(2011年5月至2015年9月,共1000例),本亚组分析纳入其中171例具备所需MRI序列者,平均年龄62岁。

诊断标准与关键阈值

  • DWI高信号病灶:MRI扩散加权成像上呈高信号,位于血肿远隔部位。
  • 血肿体积>30 cm³为DWI高信号病灶存在的独立预测因素(校正RR 2.41,95%CI 1.00–5.80)。

处置流程与药物剂量

  • 强化降压组:静脉尼卡地平,收缩压目标110–139 mmHg。
  • 标准降压组:收缩压目标140–179 mmHg。
  • 原文未提及具体剂量、输注速度及调整方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:开放标签随机试验(ATACH-2)的探索性亚组分析;样本量171例(来自1000例总样本),多中心(原文未提及具体中心数)。
  • 干预与对照:强化降压(收缩压110–139 mmHg,静脉尼卡地平)vs 标准降压(收缩压140–179 mmHg)。
  • 主要终点:DWI高信号病灶存在率,强化组25% vs 标准组24%,RR 1.01(95%CI 0.71–1.43,P=0.97)。
  • 关键次要终点:DWI高信号病灶患者与无病灶者90天死亡或残疾频率相似(原文未提供具体数值)。
  • 预测因素:血肿体积>30 cm³校正RR 2.41(95%CI 1.00–5.80)。
  • 不良事件:原文未提供本亚组分析的具体不良事件数据。

证据类型、等级与局限

  • 证据类型:随机对照试验(ATACH-2)的探索性亚组分析。
  • 局限:探索性分析、仅171例具备MRI序列、开放标签设计、亚组样本量小,结论需前瞻性验证。

对床旁实践的改变

  • 急性脑出血患者强化降压至收缩压110–139 mmHg(静脉尼卡地平)不增加DWI高信号病灶风险,支持该降压目标在影像学上的安全性。
  • 血肿体积>30 cm³的患者DWI高信号病灶风险更高(校正RR 2.41),应关注远隔部位缺血性损伤可能。
  • DWI高信号病灶与90天死亡或残疾无显著关联,不应据此改变降压决策。
  • 该分析为探索性亚组,不适用于未纳入MRI序列的患者,不能作为所有脑出血患者强化降压的充分依据。

指南或共识出处

  • ATACH-2随机试验(ClinicalTrials.gov NCT01176565)的探索性亚组分析,发表于Neurocrit Care。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: With the increasing use of magnetic resonance imaging in the assessment of acute intracerebral hemorrhage, diffusion-weighted imaging hyperintense lesions have been recognized to occur at sites remote to the hematoma in up to 40% of patients. We investigated whether blood pressure reduction was associated with diffusion-weighted imaging hyperintense lesions in acute intracerebral hemorrhage and whether such lesions are associated with worse clinical outcomes by analyzing imaging data from a randomized trial.

METHODS: We performed exploratory subgroup analyses in an open-label randomized trial that investigated acute blood pressure lowering in 1000 patients with intracerebral hemorrhage between May 2011 and September 2015. Eligible participants were assigned to an intensive systolic blood pressure target of 110-139 mm Hg versus 140-179 mm Hg with the use of intravenous nicardipine. Of these, 171 patients had requisite magnetic resonance imaging sequences for inclusion in these subgroup analyses. The primary outcome was the presence of diffusion-weighted imaging hyperintense lesions. Secondary outcomes included death or disability and serious adverse event at 90 days.

RESULTS: Diffusion-weighted imaging hyperintense lesions were present in 25% of patients (mean age 62 years). Hematoma volume > 30 cm3 was an adjusted predictor (adjusted relative risk 2.41, 95% confidence interval 1.00-5.80) of lesion presence. Lesions occurred in 25% of intensively treated patients and 24% of standard treatment patients (relative risk 1.01, 95% confidence interval 0.71-1.43, p = 0.97). Patients with diffusion-weighted imaging hyperintense lesions had similar frequencies of death or disability at 90 days, compared with patients without lesions.

CONCLUSIONS: Randomized assignment to intensive acute blood pressure lowering did not result in a greater frequency of diffusion-weighted imaging hyperintense lesion. Alternative mechanisms of diffusion-weighted imaging hyperintense lesion formation other than hemodynamic fluctuations need to be explored. Clinical trial registration ClinicalTrials.gov (Ref. NCT01176565; https://clinicaltrials.gov/ct2/show/NCT01176565 ).

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Shoamanesh A, Cassarly C, Morotti A, et al. Intensive Blood Pressure Lowering and DWI Lesions in Intracerebral Hemorrhage: Exploratory Analysis of the ATACH-2 Randomized Trial. Neurocrit Care. 2021. PMID: 34292474. doi:10.1007/s12028-021-01254-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。